Barclays Forecasts Strong Price Appreciation for DaVita (NYSE:DVA) Stock

DaVita (NYSE:DVA) had its target price increased by Barclays from $150.00 to $164.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Barclays‘s price target would suggest a potential upside of 15.89% from the company’s current price.

Several other analysts have also recently weighed in on DVA. UBS Group boosted their price objective on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Bank of America boosted their price objective on DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a report on Wednesday, August 7th. TD Cowen boosted their price objective on DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. Finally, Truist Financial boosted their price objective on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a report on Monday, October 7th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $161.80.

DaVita Stock Performance

DaVita stock opened at $141.51 on Thursday. The stock has a 50-day simple moving average of $157.71 and a 200 day simple moving average of $146.05. The company has a quick ratio of 1.12, a current ratio of 1.37 and a debt-to-equity ratio of 15.78. DaVita has a 12-month low of $76.64 and a 12-month high of $168.50. The stock has a market capitalization of $11.60 billion, a price-to-earnings ratio of 15.27, a P/E/G ratio of 0.79 and a beta of 0.89.

DaVita (NYSE:DVA) last released its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). The business had revenue of $3.26 billion during the quarter, compared to the consensus estimate of $3.25 billion. DaVita had a net margin of 6.53% and a return on equity of 88.18%. The business’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.85 earnings per share. On average, research analysts anticipate that DaVita will post 9.73 earnings per share for the current fiscal year.

Insider Transactions at DaVita

In other news, CEO Javier Rodriguez sold 50,000 shares of the business’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the completion of the transaction, the chief executive officer now directly owns 837,835 shares in the company, valued at approximately $138,284,666.75. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CFO Joel Ackerman sold 64,029 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $155.06, for a total value of $9,928,336.74. Following the completion of the transaction, the chief financial officer now directly owns 111,481 shares in the company, valued at approximately $17,286,243.86. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Javier Rodriguez sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $165.05, for a total value of $8,252,500.00. Following the completion of the transaction, the chief executive officer now owns 837,835 shares of the company’s stock, valued at $138,284,666.75. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 173,482 shares of company stock worth $27,387,069. 2.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On DaVita

Institutional investors and hedge funds have recently modified their holdings of the business. Transcendent Capital Group LLC acquired a new position in DaVita during the 3rd quarter worth approximately $25,000. Blue Trust Inc. boosted its position in DaVita by 58.6% during the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company’s stock worth $29,000 after acquiring an additional 78 shares during the last quarter. Family Firm Inc. acquired a new position in DaVita during the 2nd quarter worth approximately $43,000. Versant Capital Management Inc boosted its position in DaVita by 90.6% during the 2nd quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock worth $45,000 after acquiring an additional 155 shares during the last quarter. Finally, Friedenthal Financial acquired a new position in DaVita during the 2nd quarter worth approximately $48,000. 90.12% of the stock is currently owned by institutional investors and hedge funds.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.